Novel Strategy To Adapt Simian-Human Immunodeficiency Virus E1 Carrying from an RV144 Volunteer to Rhesus Macaques: Coreceptor Switch and Final Recovery of a Pathogenic Virus with Exclusive R5 Tropism.

The phase III RV144 human immunodeficiency virus (HIV) vaccine trial conducted in Thailand remains the only study to show efficacy in decreasing the HIV acquisition risk. In Thailand, circulating recombinant forms of HIV clade A/E (CRF01_AE) predominate; in such viruses, originates from clade E (HIV-E). We constructed a simian-human immunodeficiency virus (SHIV) chimera carrying isolated from an RV144 placebo recipient in the SHIV-1157ipd3N4 backbone.